Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Vaylen vs Found

Both scored on the same six-factor Match Score. Found wins this matchup with a 88 to 87 edge — a photo finish.

Vaylen

#5 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen
VS
Higher Match Score

Found

#2 · Grade B+

People who want the lowest price and behavior-change coaching bundled with medication.

Visit Found

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
96
Speed to Start
88
90
Formulary Match
94
80
Support Level
86
92
Flexibility
86
78
Transparency
88
90

Price, coverage & formulary

DetailVaylenFound
Semaglutide$179/mo$129/mo
Tirzepatide$239/mo$129/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjectable only
Match Score87 · B+88 · B+
Winner: Found

Found edges out Vaylen, 88 to 87 on the default Match Score. A coaching-first program with aggressive, identical pricing on both molecules — the budget match to beat.

Vaylen is still a fair pick if its strengths line up with yours — best for: People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Vaylen reviewFull Found review

More head-to-heads

Or browse alternatives to Found and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.